Marburg virus vaccines
AssigneeThe United States of America as represented by the Secretary of the Army
InventorsMichael C. Hevey, Diane L. Negley, Peter Pushko, Jonathan F. Smith, Alan L. Schmaljohn
Life of this patent
Estimating the term…
Abstract
Using the MBGV GP, NP, and virion proteins, a method and composition for use in inducing an immune response which is protective against infection with MBGV in nonhuman primates is described.
Claims24
A recombinant DNA construct comprising:
- (i) a vector, and
- (ii) at least one of the MBGV virus DNA fragments encoding any one of GP, NP, VP40, VP35, VP30, VP24, and GPΔTM.
A vaccine for MBGV comprising viral particles containing one or more replicon RNA encoding one or more MBGV proteins selected from the group consisting of GP, NP, VP24, VP30, VP35, VP40, and GPΔTM.
A pharmaceutical composition comprising one or more recombinant DNA constructs chosen from the group consisting of pRep Mus GP, pRep Mus GPΔTM, pRep Mus NP, pRep Mus VP40, pRep Mus VP35, pRep Mus VP30, pRep Mus VP24 in a pharmaceutically acceptable amount, in a pharmaceutically accpetable carrier/and or adjuvant.
Dependencies are inferred from the claim text.